30 closest matches · ranked by relevance
Bloodstream Infections (BSI) Due to CRE · Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE · Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE
Primary: Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat…
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
Pneumonia · Blood Stream Infection
Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Urinary Tract Infection · Infection Due to ESBL Bacteria · Environmental Contamination of ESBL
Primary: Treatment Failure — 23; 101 Treatment success
Urinary Tract Infection Complicated · Acute Pyelonephritis · Hospital Acquired Bacterial Pneumonia
Primary: Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success…
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Healthcare-associated Pneumonia (HCAP) · Bloodstream Infections (BSI) · Hospital Acquired Pneumonia (HAP)
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis — 50.0; 52.6; 43.5; 42.9 percentage of participants
Urinary Tract Infection · Acute Pyelonephritis · Hospital Acquired Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit - Microbiologically Modified Intent-to-Treat (mMITT) Analysis Set — 59.3; 25.9 Percentage of…
Bacteremia
Primary: Cure Rate — 207; 209 Participants
Gram-Negative Bacterial Infections
Primary: Probability of Target Attainment for 40% fT>MIC — 100; 100 percentage of time above MIC
Sepsis
Primary: Imipenem Clearance — 17.31 L/h
Sepsis · AKI · Neurotoxicity
Primary: Acute Kidney Injury (AKI) Ordinal Scale — 910; 952; 86; 100 Participants
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
Complicated Intra-Abdominal Infection
Primary: Duration of Hospitalization — 14.1 Days
Parenteral Nutrition · Blood Stream Infection
Primary: Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB) — 127; 106 Participants
Bacterial Infections
Primary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL
Sepsis
Primary: Imipenem Clearance — 15.21 Liters per hour
Infection
Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05
Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Endocarditis
Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants
Gram-negative Bacteremia
Primary: Hours to First Antibiotic Modification — 24.7; 19.0 hours — p=0.013
Bacterial Infections
Primary: Percentage of Participants With Favorable Overall Response (FOR) — 71.4; 70.0 Percentage of Participants
Bacteremia · Fungemia · Bloodstream Infection
Primary: Duration of Antimicrobial Therapy (Hours) — 44; 42; 42; 8.2 hours — p=0.92
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Cystic Fibrosis · Cystic Fibrosis Pulmonary Exacerbation · Pseudomonas Aeruginosa Infection
Primary: Ceftolozane Clearance — 4.76 Liters per hour
Sepsis · Severe Sepsis
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 4 participants
BK Virus Infection
Primary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
Methicillin-resistant Staphylococcus Aureus
Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026